Please try another search
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Name | Age | Since | Title |
---|---|---|---|
Michael Baker | - | 2020 | CEO, MD & Director |
Thomas Duthy | - | 2023 | Non-Executive Chair |
Reuben Benjamin | - | 2021 | Member of Scientific Advisory Board |
Elizabeth Stoner | 73 | 2021 | Non-Executive Director |
Anastasios Karadimitris | - | - | Chairman of Scientific Advisory Board |
Gary Jonathan Phillips | 62 | 2022 | Independent Non-Executive Director |
John Maher | - | 2021 | Member of Scientific Advisory Board |
Debora Barton | 47 | 2021 | Independent Non-Executive Director |
Gianpietro Dotti | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review